MYH9
MYH9 (Myosin-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Breast cancer, Colorectal cancer and 5 more.
Overview
Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialised functions such as secretion and capping. Required for cortical actin clearance prior to oocyte exocytosis. Promotes cell motility in conjunction with S100A4.
Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes affected pathway 0.57, literature 0.99, genetic association 0.00, somatic mutation 0.88, animal model 0.59). IntOGen calls it a driver in 11 cohorts (3 activating, 8 loss-of-function), covering Basal Cell Carcinoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MYH9 (Myosin-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Breast cancer, Colorectal cancer and 5 more.
- 1 · What it is
MYH9 (Myosin-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Breast cancer, Colorectal cancer and 5 more.
- 2 · What goes wrong in cancer
Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialised functions such as secretion and capping. Required for cortical actin clearance prior to oocyte exocytosis.
- 3 · How drugs use it
No product in this corpus aims at MYH9 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:7579 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P35579 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000100345 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.54, gastric cancer 0.54, ovarian cancer 0.54, melanoma 0.55, skin cancer 0.54, breast cancer 0.59 (GraphQL API, CC0)); IntOGen MYH9 (driver in 11 cohorts (Act 3, LoF 8); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialised functions such as secretion and capping. Required for cortical actin clearance prior to oocyte exocytosis. Promotes cell motility in conjunction with S100A4. During cell spreading, plays an important role in cytoskeleton reorganisation, focal contact formation (in the margins but not the central part of spreading cells), and lamellipodial retraction; this function is mechanically antagonised by MYH10. Location: Cytoplasm, cytoskeleton; Cytoplasm, cell cortex; Cytoplasmic vesicle, secretory vesicle, Cortical granule; Cell membrane (UniProt). Locus 22q12.3 (HGNC).
- Head and neck squamous cell carcinoma: IntOGen driver in 2 cohorts (HNSC)
- Breast cancer: Open Targets association 0.59 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Colorectal cancer: Open Targets association 0.54 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COADREAD)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.54 with gastric cancer (MONDO_0001056); IntOGen driver in 1 cohort (STOMACH)
- Ovarian cancer: Open Targets association 0.54 with ovarian cancer (MONDO_0008170); IntOGen driver in 1 cohort (OVT)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 8 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"MYH9" OR ABSTRACT:"MYH9" OR TITLE:"myosin heavy chain 9" OR ABSTRACT:"myosin heavy chain 9" OR TITLE:"Myosin-9" OR ABSTRACT:"Myosin-9" OR TITLE:"NMMHCA" OR ABSTRACT:"NMMHCA" OR TITLE:"NMHC-II-A" OR ABSTRACT:"NMHC-II-A" OR TITLE:"EPSTS" OR ABSTRACT:"EPSTS") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MYH9, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNCOR1
Shares Lung cancer (all types), Bladder & urothelial cancer, Breast cancer (all types), IntOGen.
- TargetNRG1
Shares Lung cancer (all types), Oesophageal cancer, Breast cancer (all types), IntOGen.
- TargetKAT6A
Shares Lung cancer (all types), Oesophageal cancer, Breast cancer (all types), IntOGen.
- TargetKDM6A
Shares Lung cancer (all types), Oesophageal cancer, Bladder & urothelial cancer, Breast cancer (all types).
- TargetRECQL4
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Gastric & gastro-oesophageal junction cancer.
- TargetPIK3CB
Shares Lung cancer (all types), Bladder & urothelial cancer, Breast cancer (all types), IntOGen.
- TargetLRP1B
Shares Lung cancer (all types), Oesophageal cancer, Breast cancer (all types), IntOGen.
- TargetBARD1
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Gastric & gastro-oesophageal junction cancer.